BRETEC Stock Overview
A medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bioretec Oy Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.14 |
| 52 Week High | €3.01 |
| 52 Week Low | €1.71 |
| Beta | 0 |
| 1 Month Change | 15.05% |
| 3 Month Change | -22.74% |
| 1 Year Change | -1.83% |
| 3 Year Change | -24.91% |
| 5 Year Change | n/a |
| Change since IPO | -27.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| BRETEC | FI Medical Equipment | FI Market | |
|---|---|---|---|
| 7D | -2.3% | 2.2% | -1.3% |
| 1Y | -1.8% | 4.5% | -8.4% |
Return vs Industry: BRETEC underperformed the Finnish Medical Equipment industry which returned 4.5% over the past year.
Return vs Market: BRETEC exceeded the Finnish Market which returned -8.4% over the past year.
Price Volatility
| BRETEC volatility | |
|---|---|
| BRETEC Average Weekly Movement | 7.7% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in FI Market | 7.6% |
| 10% least volatile stocks in FI Market | 2.8% |
Stable Share Price: BRETEC's share price has been volatile over the past 3 months compared to the Finnish market.
Volatility Over Time: BRETEC's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Finnish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Alan Donze | bioretec.com |
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; ActivaPin, a bioabsorbable implant for upper and lower limb fractures; and ActivaScrew, an absorbable surgical implant that is used in fracture treatment, osteotomy, arthrodesis, and bone graft surgery. It also provides ActivaScrew Cannulated that offers a range of fully threaded and partially threaded cannulated screws for fixation of fractures and osteotomies; ActivaScrew Interference, a tool for multiple uses regarding bone fractures, osteotomies, arthrodesesm, and bone grafts; ActivaScrew Interference TCP, a biocomposite interference screw; and RemeOs Screw, a magnesium screw implants.
Bioretec Oy Fundamentals Summary
| BRETEC fundamental statistics | |
|---|---|
| Market cap | €43.52m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs BRETEC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRETEC income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did BRETEC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 14:43 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bioretec Oy is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Lepistö | Danske Bank |
| Marianne Palmu | Inderes Oy |
| Frans-Mikael Rostedt | Inderes Oy |